Analysis of U.S. Patent 5,030,632: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,030,632 (issued July 9, 1991 to SmithKline Beecham Corporation, now part of GSK) pertains to a process for the synthesis of certain antihistamine compounds, specifically cetirizine and its intermediates. The patent claims a novel method of manufacturing cetirizine, which led to commercial applications, notably for allergy treatments. Its scope encompasses chemical processes, intermediate compounds, and derivatives related to cetirizine synthesis.
This report provides an in-depth examination of the patent's claims, technological scope, and the broader patent landscape, including potential infringements, licensing opportunities, and the evolution of related patent rights in the antihistamine chemical class.
1. Scope and Overview of the Patent
A. Patent Title and Abstract
Title: "Process for the preparation of cetirizine and intermediates"
Abstract: Discloses a process for preparing cetirizine, emphasizing improved synthetic steps with specific intermediates and reaction conditions, particularly acylation and cyclization steps optimized for efficiency and purity.
B. Key Novelty Elements
- Use of a specific process route avoiding prior art methods with undesirable impurities.
- Introduction of intermediates (e.g., 2-(2-Hydroxyphenyl)glycine derivatives).
- Novel reaction conditions (solvents, catalysts, temperatures).
C. Patent Classification
- USPC (United States Patent Classification):
- 514/12 (Organic compounds—heterocyclic compounds)
- 530/357 (Drug and medicinal compositions—antihistamines)
- 564/245 (Preparation of specific chemical compounds)
2. Main Claims and their Technological Scope
A. Claim Analysis
| Claim Type |
Number |
Scope |
Details |
Implications |
| Product |
1 |
Broad |
Cetirizine free base and its pharmaceutically acceptable salts |
Provides patent protection for cetirizine compounds across forms |
| Process |
2-12 |
Narrower |
Specific synthetic routes including steps like acylation, cyclization, and salt formation |
Protects particular process steps, reaction conditions |
| Intermediate compounds |
13-20 |
Narrow |
Specific chemical intermediates (e.g., amino acids, acyl derivatives) |
Covers precursor compounds for cetirizine synthesis |
B. Claim Scope Breakdown
| Claim Type |
Scope |
Coverage |
Notes |
| Composition of Matter |
Broad |
All cetirizine compounds via claimed process |
Encompasses all forms of cetirizine produced per the patent |
| Method of Preparation |
Process-specific |
Synthetic routes involving particular intermediates |
Claims are restricted to steps involving specific reaction conditions and intermediates |
| Intermediate Compounds |
Chemical building blocks |
Precursors used to synthesize cetirizine |
Can be subject to separate patent rights ifNovel and non-obvious |
C. Critical Examination of Claims
- The broadest claim (Claim 1) covers all cetirizine compounds, including salts, which has sustained its enforceability.
- Process claims specify reaction conditions, limiting infringement risk but allowing for alternative synthetic routes outside scope.
- Claims on intermediates are essential for licensing but are narrower due to prior art.
3. Patent Landscape and Related Patents
A. Related Patents and Priority
| Patent Number |
Filing Date |
Assignee |
Title |
Scope |
Notes |
| U.S. 4,391,909 |
1982 |
Glaxo (predecessor to GSK) |
Cetirizine compound |
Early synthesis methods |
Priority patent for cetirizine compounds; basis for later process patents |
| U.S. 4,645,878 |
1984 |
GSK |
Process improvements |
Modified synthetic routes |
Complemented 5,030,632, possibly creating a landscape of overlapping claims |
| WO Patent 88/03420 |
1988 |
GSK |
Improved process for cetirizine |
International patent, process-specific |
Broader process claims |
B. Patent Families and Infringement Risks
- The patent family includes related patents covering different process variations and intermediates.
- Infringement typically occurs if a process employs the patented steps or intermediates.
- Generic manufacturers have developed alternative synthetic routes avoiding patented steps, leading to 'design-around' strategies.
C. Patent Expiry and Status
| Year of Expiry |
Significance |
Details |
| 2008 |
Patent expiration |
Patent rights for process and compound claims expired, allowing generics to enter the U.S. market |
4. Comparison with Modern Synthesis and Patent Strategies
| Aspect |
Patent 5,030,632 |
Contemporary Approaches |
Implications |
| Process specificity |
Detailed reaction conditions |
Use of novel catalysts and green chemistry principles |
New methods may circumvent the patent |
| Intermediate claims |
Included |
Focus on more complex or optimized intermediates |
Broaden scope of patent coverage |
| Compound claims |
Exact cetirizine compounds |
Patents now increasingly focus on polymorphs, formulations |
Can limit generic entry or offer licensing opportunities |
5. Broader Patent Landscape in Antihistamines
| Patent Area |
Key Technologies |
Relevant Patents |
Industry Trends |
| Chemical synthesis |
Multi-step synthesis, intermediates |
Several (e.g., 4,391,909; 4,645,878) |
Shift to more cost-efficient, eco-friendly processes |
| Formulations |
Extended-release, combination drugs |
Later patents post-2000 |
Diversification of product claims |
| Polymorphs & Crystals |
Solid-state chemistry |
Recent patents (post-2010) |
Used for extension of patent life |
Conclusion
U.S. Patent 5,030,632 served as a foundational patent covering the synthesis of cetirizine, significant for both its chemical scope and process claims. It effectively protected key process steps and intermediates, influencing subsequent patent filings in antihistamine chemistry. With expiration around 2008, generic manufacturers have leveraged this patent landscape to produce formulations more affordably, though modern patent strategies have shifted toward polymorphs and formulations.
The patent landscape reveals a layered approach: initial broad compound claims followed by process-specific patents and later documentation of new solid forms. Understanding this landscape enables stakeholders to navigate licensing, infringement risks, and innovation pathways efficiently.
Key Takeaways
- Scope: The patent primarily protects cetirizine compounds and specific synthetic processes, with broad compound claims bolstered by narrow process claims.
- Patent Life: Expired in 2008, opening the field for generics.
- Infringement Risk: Controlled through process specifics—alternative routes may avoid infringement.
- Strategic Relevance: Modern patent strategies focus on polymorphs and formulations, beyond initial process claims.
- Landscape: Overlaps with other patents in intermediates and process improvements, necessitating careful freedom-to-operate analyses for new developments.
FAQs
1. Can a new synthesis route for cetirizine infringe U.S. Patent 5,030,632?
Infringement depends on whether the route employs the patented process steps, intermediates, or compounds. Non-infringing routes avoiding these specifics are legally permissible.
2. Are the claims in Patent 5,030,632 still enforceable?
No, the patent expired in 2008, removing enforceability but allowing generic competition and research freedom.
3. Does the patent cover all salts of cetirizine?
Claim 1 encompasses all pharmaceutically acceptable salts, but later patents or formulations may be separately protected.
4. How does the patent landscape influence current antihistamine innovation?
Post-expiration, focus has shifted to drug formulations, polymorphs, and new delivery systems, with process patents playing a lesser role.
5. What strategies do companies use to avoid patent infringement in cetirizine synthesis?
Employing alternative synthetic pathways, different intermediates, or skipping patented steps constitutes common design-around approaches.
References
[1] U.S. Patent 5,030,632. "Process for the preparation of cetirizine and intermediates."
[2] GSK Patent Portfolio. International patents related to cetirizine.
[3] Patent expiration notices and legal status reports (USPTO).
